Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Feasibility and Safety of Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Locally-Advanced Gastric Cancer Patients in China

View ORCID ProfileSah Birendra Kumar, Xu Wei, Zhang Benyan, Zhang Huan, Yuan Fei, Li Jian, Liu Wentao, Chao Yan, Li Chen, Yan Min, Zhu Zhenggang
doi: https://doi.org/10.1101/2020.05.22.20110668
Sah Birendra Kumar
1Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Postal add: 197 Ruijin Er Road, Shanghai-200025, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sah Birendra Kumar
  • For correspondence: rjsurgeon@hotmail.com
Xu Wei
2Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhang Benyan
3Department of Pathology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhang Huan
4Department of Radiology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Fei
3Department of Pathology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Jian
5Clinical Research Center, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liu Wentao
2Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chao Yan
2Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital Shanghai Jiao Tong University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Chen
6Department of General Surgery, Gastrointestinal Surgery Unit Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rjsurgeon@hotmail.com
Yan Min
6Department of General Surgery, Gastrointestinal Surgery Unit Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhu Zhenggang
7Department of General Surgery, Gastrointestinal Surgery Unit, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rjsurgeon@hotmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Neoadjuvant fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) has shown significant benefits for gastric cancer patients. However, it has not been well accepted in Asian countries. We conducted a prospective study on the safety and feasibility of the FLOT regimen in Chinese patients.

Methods Patients with adenocarcinoma of the stomach or esophagogastric junction received 4 cycles of neoadjuvant chemotherapy (NAC) and 4 cycles of adjuvant chemotherapy (AC) with the FLOT regimen. The completion status of chemotherapy, adverse events, postoperative morbidities, and pathological tumor regression were analyzed. The two-year overall survival (OS) and relapse-free survival are presented.

Results Altogether, 10 patients were enrolled, and all patients completed 4 cycles of neoadjuvant chemotherapy. There were no severe hematological adverse events (grade 3 or above), except for a case of grade 3 anemia. All 10 patients underwent radical gastrectomy. Nine patients had R0 resection, and 3 patients had complete or subtotal pathological tumor regression. Nine patients completed 4 cycles of adjuvant chemotherapy, but only one patient completed the full dose of adjuvant chemotherapy. The dose of adjuvant chemotherapy was reduced by 25% or less in the other patients. The median follow-up time was 23.13 months, 8 patients achieved the overall survival endpoint, and 7 patients had relapse-free survival for this period. Two patients died of disease progression.

Conclusions Our study demonstrates that the neoadjuvant FLOT regimen is safe and effective for Chinese patients. Dose adjustment is necessary for adjuvant chemotherapy. The pathological regression and survival rates need reevaluation in a larger cohort.

The trial is registered with ClinicalTrials.gov (number NCT03646591).

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ClinicalTrials.gov, number NCT03646591.

Funding Statement

The overall costs of publication will be funded by grants from the National Natural Science Foundation of China (No. 91529302 (BY Liu), No.81772509 (Liu BY), No. 81572798 (Su LP), No.81871902 (Su LP), and No. 81871904 (Zhu ZG)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted and analyzed by Unit III of the Gastrointestinal department, Ruijin Hospital. The study was done according to the Declaration of Helsinki and Good Clinical Practice Guidelines as defined by the International Conference on Harmonisation. The study was approved by the Institutional Review Board, Ruijin Hospital. Patients gave written informed consent for planned treatment.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵‡ Co-first author

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 28, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Feasibility and Safety of Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Locally-Advanced Gastric Cancer Patients in China
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Feasibility and Safety of Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Locally-Advanced Gastric Cancer Patients in China
Sah Birendra Kumar, Xu Wei, Zhang Benyan, Zhang Huan, Yuan Fei, Li Jian, Liu Wentao, Chao Yan, Li Chen, Yan Min, Zhu Zhenggang
medRxiv 2020.05.22.20110668; doi: https://doi.org/10.1101/2020.05.22.20110668
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Feasibility and Safety of Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Locally-Advanced Gastric Cancer Patients in China
Sah Birendra Kumar, Xu Wei, Zhang Benyan, Zhang Huan, Yuan Fei, Li Jian, Liu Wentao, Chao Yan, Li Chen, Yan Min, Zhu Zhenggang
medRxiv 2020.05.22.20110668; doi: https://doi.org/10.1101/2020.05.22.20110668

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (455)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (159)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5292)
  • Forensic Medicine (3)
  • Gastroenterology (198)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (214)
  • Health Informatics (701)
  • Health Policy (361)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (165)
  • Infectious Diseases (except HIV/AIDS) (5925)
  • Intensive Care and Critical Care Medicine (366)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (772)
  • Nursing (43)
  • Nutrition (133)
  • Obstetrics and Gynecology (145)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (153)
  • Orthopedics (39)
  • Otolaryngology (97)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (137)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2034)
  • Radiology and Imaging (354)
  • Rehabilitation Medicine and Physical Therapy (159)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)